News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dendreon Corporation (DNDN) Announces Presentation Of PROVENGE┬« (sipuleucel-T) And DN24-02 Immuno-Oncology Data At The 2014 American Society of Clinical Oncology Annual Meeting



5/15/2014 8:08:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Dendreon Corporation (NASDAQ:DNDN) announced today the presentation of two PROVENGE® (sipuleucel-T) abstracts from the Phase II STAND study and the PROCEED registry, and one abstract highlighting data from the ongoing Phase II study of DN24-02, an investigational active cellular immunotherapy for patients with surgically resected HER2+ urothelial cancer.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES